Bellicum Pharmaceuticals, Inc.
BLCM · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $22 | $17 | $20 | $60 |
| - Cash | $22 | $46 | $35 | $91 |
| + Debt | $0 | $0 | $1 | $38 |
| Enterprise Value | $0 | -$29 | -$14 | $7 |
| Revenue | $2 | $6 | $1 | $7 |
| % Growth | -75.8% | 1,140% | -93% | – |
| Gross Profit | $2 | $6 | $1 | $7 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$27 | -$24 | $2 | -$87 |
| % Margin | -1,798.7% | -392.7% | 478.2% | -1,223.1% |
| Net Income | -$25 | -$10 | -$9 | -$126 |
| % Margin | -1,664.9% | -154.5% | -1,723.8% | -1,765.3% |
| EPS Diluted | -0.81 | -0.83 | -1.5 | -26.92 |
| % Growth | 2.4% | 44.7% | 94.4% | – |
| Operating Cash Flow | -$26 | -$23 | -$57 | -$78 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$1 |
| Free Cash Flow | -$26 | -$23 | -$57 | -$78 |